Llwytho...
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
BACKGROUND & AIMS: There are few real-world data on the safety of vedolizumab for treatment of Crohn’s disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious and non-infectious adverse events in clinical practice. METHODS: We...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Clin Gastroenterol Hepatol |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594363/ https://ncbi.nlm.nih.gov/pubmed/30268561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2018.09.035 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|